Bausch Health Companies Inc.
BHCNYSEHealthcare● Active
$5.37
+$0.11(+2.09%)
Market Cap$2.0B
P/E Ratio—
52W High$8.69
52W Low$4.61
Bausch Health Companies Inc. (BHC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BHC · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
$0.78
Est. $0.81 · -3.7%
Revenue
$2.47B
Est. $2.37B · +4.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
BHC reports quarterly as a NYSE-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 29, 2026 | $0.96 | — | — | — | $2.60B | — |
| ▼ Q2 FY2026 | Apr 29, 2026 | $0.81 | $0.78 | -3.7% | $2.47B | $2.37B | +4.3% |
| ▼ Q1 FY2026 | Feb 18, 2026 | $1.21 | $1.08 | -10.7% | $2.79B | $2.73B | +2.1% |
| ▲ Q4 FY2025 | Oct 29, 2025 | $1.07 | $1.16 | +8.4% | $2.68B | $2.71B | -1.1% |
| ▼ Q3 FY2025 | Jul 30, 2025 | $0.97 | $0.90 | -7.2% | $2.53B | $2.58B | -2.1% |
| ▼ Q2 FY2025 | Apr 30, 2025 | $0.83 | $0.59 | -28.9% | $2.26B | $2.48B | -8.9% |
| ▼ Q1 FY2025 | Feb 19, 2025 | $1.65 | $1.15 | -30.3% | $2.56B | $2.29B | +11.9% |
| ▲ Q4 FY2024 | Oct 30, 2024 | $1.03 | $1.12 | +8.7% | $2.51B | $2.52B | -0.3% |
Q3 FY2026
Jul 29, 2026
EPS Actual
—
EPS Est.
$0.96
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Miss
EPS Actual
$0.78
EPS Est.
$0.81
EPS Surpr.
-3.7%
Revenue
$2.47B
Q1 FY2026
Feb 18, 2026Miss
EPS Actual
$1.08
EPS Est.
$1.21
EPS Surpr.
-10.7%
Revenue
$2.79B
Q4 FY2025
Oct 29, 2025Beat
EPS Actual
$1.16
EPS Est.
$1.07
EPS Surpr.
+8.4%
Revenue
$2.68B
Q3 FY2025
Jul 30, 2025Miss
EPS Actual
$0.90
EPS Est.
$0.97
EPS Surpr.
-7.2%
Revenue
$2.53B
Q2 FY2025
Apr 30, 2025Miss
EPS Actual
$0.59
EPS Est.
$0.83
EPS Surpr.
-28.9%
Revenue
$2.26B
Q1 FY2025
Feb 19, 2025Miss
EPS Actual
$1.15
EPS Est.
$1.65
EPS Surpr.
-30.3%
Revenue
$2.56B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
$1.12
EPS Est.
$1.03
EPS Surpr.
+8.7%
Revenue
$2.51B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $1.18 | $1.20 | $1.22 | 2 |
| Q3 FY2027 | $1.07 | $1.08 | $1.10 | 1 |
| Q2 FY2027 | $0.90 | $0.91 | $0.92 | 1 |
| Q1 FY2027 | $0.74 | $0.75 | $0.76 | 2 |
| Q4 FY2026 | $1.31 | $1.32 | $1.35 | 2 |
| Q3 FY2026 | $1.22 | $1.24 | $1.25 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $2.8B | $2.8B | $2.8B | 1 |
| Q3 FY2027 | $2.6B | $2.7B | $2.7B | 2 |
| Q2 FY2027 | $2.6B | $2.6B | $2.6B | 2 |
| Q1 FY2027 | $2.4B | $2.4B | $2.4B | 1 |
| Q4 FY2026 | $2.8B | $2.8B | $2.8B | 2 |
| Q3 FY2026 | $2.7B | $2.7B | $2.7B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 29, 2026 | -3.7% | $5.67 | $5.59 | -1.41% |
| ▼ Q1 FY2026 | Feb 18, 2026 | -10.7% | $5.99 | $6.19 | +3.34% |
| ▲ Q4 FY2025 | Oct 29, 2025 | +8.4% | $6.19 | $5.90 | -4.68% |
| ▼ Q3 FY2025 | Jul 30, 2025 | -7.2% | $6.82 | $6.39 | -6.30% |
| ▼ Q2 FY2025 | Apr 30, 2025 | -28.9% | $5.51 | $5.30 | -3.81% |
| ▼ Q1 FY2025 | Feb 19, 2025 | -30.3% | $6.36 | $6.51 | +2.36% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +8.7% | $8.16 | $8.17 | +0.12% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +1.1% | $6.03 | $6.10 | +1.16% |
Q2 FY2026-1.41%
Report Date
Apr 29, 2026
EPS Beat/Miss
-3.7%
Price Before
$5.67
Price After
$5.59
Q1 FY2026+3.34%
Report Date
Feb 18, 2026
EPS Beat/Miss
-10.7%
Price Before
$5.99
Price After
$6.19
Q4 FY2025-4.68%
Report Date
Oct 29, 2025
EPS Beat/Miss
+8.4%
Price Before
$6.19
Price After
$5.90
Q3 FY2025-6.30%
Report Date
Jul 30, 2025
EPS Beat/Miss
-7.2%
Price Before
$6.82
Price After
$6.39
Q2 FY2025-3.81%
Report Date
Apr 30, 2025
EPS Beat/Miss
-28.9%
Price Before
$5.51
Price After
$5.30
Q1 FY2025+2.36%
Report Date
Feb 19, 2025
EPS Beat/Miss
-30.3%
Price Before
$6.36
Price After
$6.51
Q4 FY2024+0.12%
Report Date
Oct 30, 2024
EPS Beat/Miss
+8.7%
Price Before
$8.16
Price After
$8.17
Q3 FY2024+1.16%
Report Date
Aug 1, 2024
EPS Beat/Miss
+1.1%
Price Before
$6.03
Price After
$6.10
Avg Beat Reaction-1.13%
Avg Miss Reaction-1.16%
Beat Rate3 / 8 quarters
Largest Move-6.30% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BHC ends December
Bausch Health Companies Inc. (BHC) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $0.78 — missing the analyst consensus of $0.81 by -3.7%. The next BHC earnings date is expected around September 1, 2026.
Each quarter, investors track BHC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BHC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BHC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BHC earnings · 5 questionsBausch Health Companies Inc.'s next earnings report is expected around September 1, 2026. BHC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BHC historically reports after market close (AMC).
BHC earnings datewhen is BHC earningsBHC next earnings datewhen does BHC report earningsBHC earnings calendar
▸ Source: FMP · Bausch Health Companies Inc. SEC filings · US GAAP · Bausch Health Companies Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026